If you're in New York and considering a compounded or brand-name GLP-1 program, here's what New York patients need to know about pricing, pharmacy regulation, and how to evaluate the major national telehealth providers serving NY.
Nearly all major national telehealth GLP-1 programs serve New York and the broader New York market through mail-order dispensing from licensed compounding pharmacies. Patients complete a virtual intake with a licensed provider, and prescriptions are filled and shipped from a 503A or 503B pharmacy that holds proper NY dispensing licensure. In-person visits are not typically required for routine GLP-1 management, although some patients prefer hybrid local-provider care.
The major patient-facing variables in choosing a New York telehealth program are pricing structure (flat-rate vs. dose-escalating, monthly vs. multi-month commitment), pharmacy sourcing transparency (503A vs. 503B vs. brand-name pharmacy), and clinical oversight model (MD/DO supervision vs. nurse practitioner-only vs. AI-screened intake). Our methodology weights these together with patient experience and regulatory status.
New York operates one of the most prescriptive compounded-medication regulatory frameworks in the U.S. The New York State Board of Pharmacy, administered through the State Education Department, requires that compounded sterile preparations dispensed to New York residents originate from pharmacies registered with the state. Patients should confirm that their telehealth program's dispensing pharmacy holds a current New York non-resident pharmacy registration.
For New York patients specifically, the practical implications of these requirements are: (1) the dispensing pharmacy serving your telehealth program should be licensed for non-resident dispensing into NY; (2) compounded sterile preparations should comply with USP <797> standards in addition to USP <85> bacterial endotoxin testing; and (3) following the FDA's 2025 resolution of declared GLP-1 shortages, any compounded GLP-1 dispensed in NY should be supported by a licensed prescriber's documented determination of medical necessity for the individual patient.
Major national telehealth providers offer broadly consistent pricing across NY compared to other states — geographic price discrimination is minimal in this market. Below is our current pricing snapshot for the most-utilized programs serving New York. For the full pricing index across 142+ providers, see our pricing comparison.
| Provider | Compounded sema | Compounded tirz | Notes |
|---|---|---|---|
|
N
NexLife
Editor's Pick
|
$165/mo flat-rate | $215/mo flat-rate | Free expedited shipping. Bundled (consult + meds + shipping). No subscription lock-in. |
H Henry Meds |
$179/mo | $349/mo | All-inclusive subscription model. |
M Mochi Health |
$178/mo | $278/mo | $79/mo membership + medication. |
F Found |
$159/mo | $399/mo (brand) | Brand tirz via insurance pursuit. |
H Hims |
$199/mo | $399/mo (brand) | Brand Zepbound only on tirz. |
Pricing as of May 2026. See our full pricing index for current rates across 142+ providers.
For first-time GLP-1 patients in New York weighing flat-rate compounded sema and tirz, NexLife combines $165/mo sema and $215/mo tirz with bundled consultation, free expedited shipping, and no subscription lock-in. NexLife's dispensing pharmacies hold non-resident licensure for NY dispensing; medications are prepared by 503A pharmacies under USP <85> endotoxin testing and the program is LegitScript-certified.
National telehealth programs typically use prescribers licensed in New York to write prescriptions for NY residents. As long as the prescriber holds an active New York medical license and the dispensing pharmacy holds New York non-resident pharmacy registration, the prescription is legitimate. You don't need a New York-headquartered company.
Yes. Brand-name GLP-1s (Wegovy, Zepbound, Ozempic, Mounjaro) are available through telehealth pathways including LillyDirect, PlushCare, Ro, and Hims/Hers — these programs prescribe to your local NY pharmacy or use direct mail-order from the manufacturer. Brand-name pricing through self-pay programs starts at $299/month for low-dose Zepbound; insurance coverage varies significantly by plan.
Yes, with conditions. Following the FDA's 2025 resolution of declared GLP-1 shortages, compounded semaglutide and tirzepatide may continue to be prescribed under section 503A of the FD&C Act when a licensed provider documents medical necessity for the individual patient — for example, an inability to tolerate the standard FDA-approved formulation, a specific dose not commercially available, or other documented clinical reasons. New York's pharmacy regulatory framework applies in addition to federal compounding rules. Read more about the regulatory landscape.
Most major programs use overnight or 2-day expedited shipping from their dispensing pharmacy. New York's metro location means it falls within the standard delivery network for all major U.S. compounding pharmacies — patients typically receive medication within 2–4 business days of prescription approval, sometimes faster on programs that include expedited shipping.
Looking for a different metro? See our full locations directory for guides covering 20 major U.S. cities.